Abstract
43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an accelerated split-course schedule (type B) of thoracic radiation therapy and a combination chemotherapy with vinorelbine and carboplatin. An objective response was achieved in 18/42 evaluable patients (5 complete and 13 partial responses), for an overall response rate of 43% (95% confidence interval, 28-58%). Four complete responses had a duration which exceeded 16 months. Treatment was well tolerated; grade III myelotoxcity occurred in only 14% of patients and treatment was delayed in only 2 cases because of grade 3 oesophagitis. Both tolerability and efficacy data suggest that this regimen holds promise for the treatment of patients with stage III NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 1901-1904 |
| Number of pages | 4 |
| Journal | European Journal of Cancer |
| Volume | 32 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Oct 1996 |
Fingerprint
Keywords
- Accelerated split-course radiotherapy
- Carboplatin
- Non-small cell lung cancer
- Vinorelbine
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer. / Iaffaioli, R. V.; Caponigro, F.; Tortoriello, A.; Facchini, G.; Ravo, V.; Maccauro, M.; Dimitri, P.; Crovella, F.; Muto, P.
In: European Journal of Cancer, Vol. 32, No. 11, 10.1996, p. 1901-1904.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer
AU - Iaffaioli, R. V.
AU - Caponigro, F.
AU - Tortoriello, A.
AU - Facchini, G.
AU - Ravo, V.
AU - Maccauro, M.
AU - Dimitri, P.
AU - Crovella, F.
AU - Muto, P.
PY - 1996/10
Y1 - 1996/10
N2 - 43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an accelerated split-course schedule (type B) of thoracic radiation therapy and a combination chemotherapy with vinorelbine and carboplatin. An objective response was achieved in 18/42 evaluable patients (5 complete and 13 partial responses), for an overall response rate of 43% (95% confidence interval, 28-58%). Four complete responses had a duration which exceeded 16 months. Treatment was well tolerated; grade III myelotoxcity occurred in only 14% of patients and treatment was delayed in only 2 cases because of grade 3 oesophagitis. Both tolerability and efficacy data suggest that this regimen holds promise for the treatment of patients with stage III NSCLC.
AB - 43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an accelerated split-course schedule (type B) of thoracic radiation therapy and a combination chemotherapy with vinorelbine and carboplatin. An objective response was achieved in 18/42 evaluable patients (5 complete and 13 partial responses), for an overall response rate of 43% (95% confidence interval, 28-58%). Four complete responses had a duration which exceeded 16 months. Treatment was well tolerated; grade III myelotoxcity occurred in only 14% of patients and treatment was delayed in only 2 cases because of grade 3 oesophagitis. Both tolerability and efficacy data suggest that this regimen holds promise for the treatment of patients with stage III NSCLC.
KW - Accelerated split-course radiotherapy
KW - Carboplatin
KW - Non-small cell lung cancer
KW - Vinorelbine
UR - http://www.scopus.com/inward/record.url?scp=0030272386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030272386&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(96)00203-1
DO - 10.1016/0959-8049(96)00203-1
M3 - Article
C2 - 8943672
AN - SCOPUS:0030272386
VL - 32
SP - 1901
EP - 1904
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 11
ER -